Research ExplorerPublicationsAutoimmune hepatitis.

Autoimmune hepatitis.

Standard

Autoimmune hepatitis. / Lohse, Ansgar W.; Mieli-Vergani, Giorgina.

In: J HEPATOL, Vol. 55, No. 1, 1, 2011, p. 171-182.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lohse, AW & Mieli-Vergani, G 2011, 'Autoimmune hepatitis.', J HEPATOL, vol. 55, no. 1, 1, pp. 171-182. <http://www.ncbi.nlm.nih.gov/pubmed/21167232?dopt=Citation>

APA

Lohse, A. W., & Mieli-Vergani, G. (2011). Autoimmune hepatitis. J HEPATOL, 55(1), 171-182. [1]. http://www.ncbi.nlm.nih.gov/pubmed/21167232?dopt=Citation

Vancouver

Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J HEPATOL. 2011;55(1):171-182. 1.

Bibtex

@article{ab8fe38004fd45e4a1ec23929d24f65e,
title = "Autoimmune hepatitis.",
abstract = "Autoimmune hepatitis was one of the first liver diseases for which an effective treatment was developed and the benefit proven by randomized controlled trials. Nonetheless, both the diagnosis and the treatment of autoimmune hepatitis remain full of challenges. The clinical spectrum is very wide, ranging from subclinical non-progressive disease to fulminant hepatic failure. Diagnostic criteria based on elevation of IgG, demonstration of characteristic autoantibodies, and histological features of hepatitis in the absence of viral disease are very helpful. However, in some patients, diagnosis remains a clinical challenge. Adequately dosed steroids are the mainstay of remission induction treatment, while remission maintenance is best achieved by azathioprine. Therapeutic alternatives are required in a small group of patients responding insufficiently to these drugs or intolerant to their side effects.",
author = "Lohse, {Ansgar W.} and Giorgina Mieli-Vergani",
year = "2011",
language = "English",
volume = "55",
pages = "171--182",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Autoimmune hepatitis.

AU - Lohse, Ansgar W.

AU - Mieli-Vergani, Giorgina

PY - 2011

Y1 - 2011

N2 - Autoimmune hepatitis was one of the first liver diseases for which an effective treatment was developed and the benefit proven by randomized controlled trials. Nonetheless, both the diagnosis and the treatment of autoimmune hepatitis remain full of challenges. The clinical spectrum is very wide, ranging from subclinical non-progressive disease to fulminant hepatic failure. Diagnostic criteria based on elevation of IgG, demonstration of characteristic autoantibodies, and histological features of hepatitis in the absence of viral disease are very helpful. However, in some patients, diagnosis remains a clinical challenge. Adequately dosed steroids are the mainstay of remission induction treatment, while remission maintenance is best achieved by azathioprine. Therapeutic alternatives are required in a small group of patients responding insufficiently to these drugs or intolerant to their side effects.

AB - Autoimmune hepatitis was one of the first liver diseases for which an effective treatment was developed and the benefit proven by randomized controlled trials. Nonetheless, both the diagnosis and the treatment of autoimmune hepatitis remain full of challenges. The clinical spectrum is very wide, ranging from subclinical non-progressive disease to fulminant hepatic failure. Diagnostic criteria based on elevation of IgG, demonstration of characteristic autoantibodies, and histological features of hepatitis in the absence of viral disease are very helpful. However, in some patients, diagnosis remains a clinical challenge. Adequately dosed steroids are the mainstay of remission induction treatment, while remission maintenance is best achieved by azathioprine. Therapeutic alternatives are required in a small group of patients responding insufficiently to these drugs or intolerant to their side effects.

M3 - SCORING: Journal article

VL - 55

SP - 171

EP - 182

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 1

M1 - 1

ER -